GlassScriptPhysician profile
Jithendhar Kandimalla
NPI 1558943241
$531.22
in general payments reported to CMS, 2019-2025
12 companies · $312 in 2025
The $312 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $59.29 · 2024: $160 · 2025: $312.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $471 · Education: $60.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $471.22 |
| Education | $60.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Argenx US, INC. | $88.30 | 2024-2025 | Vyvgart Hytrulo |
| Alexion Pharmaceuticals, INC. | $79.99 | 2025 | Ultomiris |
| Genentech USA, INC. | $79.70 | 2024-2025 | Ocrevus Zunovo |
| Chiesi USA, INC. | $60.00 | 2024 | Cleviprex |
| Neurelis, INC. | $42.13 | 2024-2025 | Valtoco |
| Ucb, INC. | $38.81 | 2024 | Fintepla, Briviact |
| Abbvie INC. | $32.91 | 2025 | |
| Lundbeck LLC | $29.33 | 2025 | Vyepti |
| Biogen, INC. | $23.56 | 2023 | Spinraza |
| Amgen INC. | $20.76 | 2025 | Uplizna |
| Jazz Pharmaceuticals INC. | $20.13 | 2023 | Epidiolex |
| Astrazeneca Pharmaceuticals LP | $15.60 | 2023 | Brilinta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jithendhar Kandimalla listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.